5,652 results match your criteria Narcolepsy


Health-related quality of life in patients with narcolepsy types 1 and 2 from a Sleep Center in Brazil.

Arq Neuropsiquiatr 2020 Jun 29. Epub 2020 Jun 29.

Universidade Federal de São Paulo, Departamento de Psicobiologia, São Paulo SP, Brazil.

Introduction: Narcolepsy patients have higher prevalence of comorbidities, such as obesity, depression, and pain. Narcolepsy symptoms and concomitant medical conditions can impact the daily activities of patients. The objective of this study is to describe the quality of life in a sample of patients with narcolepsy, and the influence of the nutritional status in health domains. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/0004-282X20200032DOI Listing

Hyponatraemia and cerebral oedema due to a modafinil overdose.

BMJ Case Rep 2020 Jul 5;13(7). Epub 2020 Jul 5.

Brain Injury Rehabilitation Unit, North Bristol NHS Trust, Bristol, Avon, UK.

Modafinil is a non-amphetamine stimulant that is prescribed for narcolepsy-associated sleepiness as well as reported off-licence uses among university students looking to improve wakefulness and focus. There is limited information in the medical literature about supratherapeutic modafinil dosage, symptomatology and management of overdose. We report a case of a healthy 32-year-old man who was found unconscious, having vomited, with an empty modafinil blister strip. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2020-234530DOI Listing

Narcolepsy risk and COVID-19.

J Clin Sleep Med 2020 Jul 6. Epub 2020 Jul 6.

Cincinnati Children's Hospital, Cincinnati, Ohio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5664/jcsm.8668DOI Listing

Measured resting metabolic rate, respiratory quotient, and body composition in patients with narcolepsy: a preliminary report of a case-control study.

Sci Rep 2020 Jul 3;10(1):11024. Epub 2020 Jul 3.

Department of Therapeutic Nutrition, King Khalid University Hospital, King Saud University(KSU)-Medical City, King Saud University (KSU), Riyadh, Kingdom of Saudi Arabia.

This case-control study compared the body composition, resting metabolic rate (RMR), and respiratory quotient (RQ) of narcolepsy patients with those of body mass index (BMI)- gender and age-matched controls. This study included 14 male patients with narcolepsy and 14 matched controls. The narcolepsy patients were subdivided into two subgroups (n = 7/each): those with cataplexy (NT1) and those without cataplexy (NT2). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-67978-4DOI Listing

Safety of Recombinant Influenza Vaccine Compared to Inactivated Influenza Vaccine in Adults: An Observational Study.

Open Forum Infect Dis 2020 Jun 20;7(6):ofaa179. Epub 2020 May 20.

Kaiser Permanente Vaccine Study Center, Oakland, California, USA.

Background: Recombinant trivalent influenza vaccine (RIV3) was initially licensed in 2013 and approved for all adults ≥18 in 2014. This study evaluated the safety of RIV3 compared with trivalent standard-dose, inactivated influenza vaccine (IIV3) in Kaiser Permanente Northern California (KPNC).

Methods: This Phase 4 observational, postmarketing safety study included persons ≥18 years vaccinated with RIV3 or IIV3 in KPNC during the 2015-2016 influenza season. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ofid/ofaa179DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316363PMC

Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies.

Sleep Med Rev 2020 May 16;53:101339. Epub 2020 May 16.

The University of Sydney, Faculty of Science, School of Psychology, Sydney, New South Wales, Australia; Centre for Sleep and Chronobiology, Woolcock Institute of Medical Research, University of Sydney, Camperdown, New South Wales, Australia; The University of Sydney, Brain and Mind Centre, Sydney, New South Wales, Australia. Electronic address:

Cannabinoids, including the two main phytocannabinoids Δ-tetrahydrocannabinol (THC) and cannabidiol (CBD), are being increasingly utilised as pharmacological interventions for sleep disorders. THC and CBD are known to interact with the endocannabinoid and other neurochemical systems to influence anxiety, mood, autonomic function, and circadian sleep/wake cycle. However, their therapeutic efficacy and safety as treatments for sleep disorders are unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.smrv.2020.101339DOI Listing

The evolution of the narcolepsy concept in Russia: A historical view.

J Hist Neurosci 2020 Jun 30:1-15. Epub 2020 Jun 30.

Department of Neurology, Sechenov University , Moscow, Russia.

Following the first descriptions of narcolepsy with cataplexy by Westphal, Gelineau, and Fischer (1878-1880), Russian authors started to report on "narcolepsy cases" in 1894. It was, however, only in 1925 that Mankovsky reported a (postencephalitic) case, satisfying current diagnostic criteria for the disease. In the following 66 years (the last publication appeared in 1991), Russian authors including Davidenkov, Vein, and Yakhno made interesting contributions on the clinical features, neurophysiological correlates (e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0964704X.2020.1777502DOI Listing

Gamma-hydroxybutyrate abuse: pharmacology and poisoning and withdrawal management.

Arh Hig Rada Toksikol 2020 Mar;71(1):19-26

Department of Anatomical, Histological, Forensic, and Orthopaedic Sciences,Sapienza University of Rome, Rome, Italy.

Gamma-hydroxybutyrate (GHB) is a central nervous system depressant primarily used as a recreational drug of abuse, but also for the treatment of narcolepsy with cataplexy in adult patients and as an adjuvant for control of alcohol withdrawal syndrome. The main aim of this review is to summarise updated knowledge about GHB pharmacokinetics and pharmacodynamics, acute poisoning, and clinical features of GHB withdrawal syndrome, its diagnosis and medical treatment. The most common clinical signs and symptoms of acute poisoning include sleepiness to deep coma, bradycardia, hypotension, and respiratory failure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2478/aiht-2020-71-3314DOI Listing

variants in REM sleep behavior disorder: a multicenter study.

Neurology 2020 Jun 26. Epub 2020 Jun 26.

Department of Human Genetics, McGill University, Montréal, QC, Canada

Objective: To study the role of variants in the risk for isolated rapid-eye-movement (REM)-sleep behavior disorder (iRBD) and conversion to overt neurodegeneration.

Methods: A total of 4,147 individuals were included: 1,061 iRBD patients and 3,086 controls. was fully sequenced using molecular inversion probes and Sanger sequencing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000010042DOI Listing

Treatment of Isolated Cataplexy With Low-dose Aripiprazole in an Adolescent Patient.

Clin Neuropharmacol 2020 Jun 23. Epub 2020 Jun 23.

Department of Child and Adolescent Psychiatry, Ali Kemal Belviranlı Maternity and Children Hospital, Konya, Turkey.

Background: Cataplexy is a clinical entity that is characterized by transient muscle tone loss that mostly occurring as a part of narcolepsy. On the other hand, isolated cataplexy (IC) (hereditary cataplexy) is defined as loss of muscle tone that is not accompanied by narcolepsy. Emotional reactions may trigger IC episodes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WNF.0000000000000398DOI Listing

Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Randomized Controlled Trial.

CNS Drugs 2020 Jul;34(7):773-784

Montefiore Medical Center, 111 East 210th Street, Bronx, NY, 10467-2509, USA.

Background: Solriamfetol, a dopamine/norepinephrine reuptake inhibitor, improved wakefulness and reduced excessive daytime sleepiness (EDS) in studies of participants with narcolepsy with and without cataplexy.

Objective: Prespecified subgroup analyses of data from a 12-week randomized, double-blind, placebo-controlled, phase III trial of solriamfetol for EDS in narcolepsy evaluated the efficacy and safety of solriamfetol by cataplexy status.

Methods: Participants with narcolepsy received solriamfetol (75, 150, or 300 mg/day) or placebo and were stratified by cataplexy status. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40263-020-00744-2DOI Listing

Late-onset post-lesional paroxysmal hypothermia: a case series and literature review.

J Neurol 2020 Jun 22. Epub 2020 Jun 22.

Department of Functional Neurology and Epileptology, Neurological Hospital, Hospices Civils de Lyon and University of Lyon, 59 Boulevard Pinel, 69677, Bron Cedex, Lyon, France.

Background: Paroxysmal hypothermia (PH) is a rare condition characterized by recurrent episodes of spontaneous hypothermia, bradycardia, disorders of consciousness and, in some cases, hyperhidrosis. When associated with a detectable hypothalamic lesion, PH episodes usually occur shortly after the brain insult.

Methods: We performed a retrospective study to identify patients who had demonstrated at least one episode of symptomatic spontaneous PH as defined by (i) tympanic temperature < 35 °C; (ii) drowsiness and/or confusion state and/or coma; (iii) duration of the episode ≥ 24 h; (iv) absence of other condition resulting in hypothermia RESULTS: Among 8824 patients, we identified four patients with recurrent late-onset PH episodes of 1-26-day duration that occurred 6-46 years after the brain insult. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00415-020-10013-3DOI Listing

Sleep fragmentation increases blood pressure and is associated with alterations in the gut microbiome and fecal metabolome in rats.

Physiol Genomics 2020 Jun 22. Epub 2020 Jun 22.

Center for Narcolepsy, Sleep, and Health Research, University of Illinois at Chicago, United States.

The gut microbiota, via the production of metabolites entering the circulation, plays a role in blood pressure regulation. Blood pressure is also affected by the characteristics of sleep. To date, no studies have examined relationships among the gut microbiota/metabolites, blood pressure, and sleep. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1152/physiolgenomics.00039.2020DOI Listing

Extending sleep to confirm insufficient sleep syndrome is challenging.

J Sleep Res 2020 Jun 18:e13109. Epub 2020 Jun 18.

Department of Neurology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Insufficient sleep syndrome (ISS) is prevalent, but poorly studied. This descriptive study was performed to determine its diagnostic challenges and clinical characteristics in a large (n = 3,461) retrospective sample from a single sleep laboratory. Based on actigraphy, polysomnography and multiple sleep latency tests, we diagnosed "suspected insufficient sleep syndrome" in patients with chronic sleepiness, short time in bed, longer sleep duration during weekends or vacation, and without evidence of other causes of sleepiness. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jsr.13109DOI Listing

The influence of narcolepsy on olfactory function: a review.

Sleep Med 2020 Mar 31;72:75-81. Epub 2020 Mar 31.

Departamento de Psicobiologia, Universidade Federal de São Paulo, São Paulo, Brazil; Departamento de Neurologia e Neurocirurgia, Universidade Federal de São Paulo, São Paulo, Brazil. Electronic address:

Introduction: Narcolepsy is a sleep disorder associated with loss of hypocretin cells characterized by irrepressible need to sleep, often accompanied by cataplexy, sleep fragmentation, hypnagogical and hypnopompic hallucinations, and sleep paralysis. It is also correlated with alterations in the sleep-wake cycle, dysautonomia, olfactory dysfunction, and eating disorders.

Methods: This is a review about influence of narcolepsy on human olfaction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.sleep.2020.03.023DOI Listing

Narcolepsy Severity Scale: experience of a Brazilian Sleep Center.

Sleep 2020 Jun 16. Epub 2020 Jun 16.

Department of Psychobiology, Universidade Federal de São Paulo, São Paulo, Brazil.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/sleep/zsaa113DOI Listing

Anti-streptococcal antibodies in Chinese patients with type -1 narcolepsy.

Sleep Med 2020 Mar 31;72:37-40. Epub 2020 Mar 31.

Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing, 100044, China. Electronic address:

Background: Narcolepsy type 1 (NT1) is considered to be an autoimmune disease, and streptococcal infection may be an environmental trigger. However, previous studies from Asian narcolepsy patients did not reveal elevated anti-streptolysin O [ASO]. The aim is to investigate whether large sample Chinese patients with NT1 have an increase in antistreptococcal antibody titers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.sleep.2020.03.019DOI Listing

Absorption, Distribution, Metabolism, Excretion (ADME), Drug-drug interaction potential and Prediction of Human Pharmacokinetics of SUVN-G3031, a Novel Histamine 3 Receptor (HR) inverse agonist in Clinical development for the treatment of Narcolepsy.

Eur J Pharm Sci 2020 Jun 10:105425. Epub 2020 Jun 10.

Drug Metabolism and Pharmacokinetics, Suven Life Sciences Limited, Hyderabad, India.

SUVN-G3031 is a potent and selective inverse agonist of Histmine-3 (H) receptor that is being investigated for the treatment of narcolepsy. SUVN-G3031 has high passive permeability, not a substrate for P-glycoprotein, has high plasma unbound fractions and was equally distributed between blood and plasma. Major routes of metabolism in vitro were cyclization (Metabolite A) in microsomes and dealkylation (Metabolite D) in hepatocytes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejps.2020.105425DOI Listing

Orexin cell transplant reduces behavioral arrest severity in narcoleptic mice.

Brain Res 2020 Jun 9:146951. Epub 2020 Jun 9.

Departamento de Neuropatología Molecular, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Circuito Exterior s/n, Ciudad Universitaria, Coyoacán, Ciudad de México 04510, Mexico.

Narcolepsy is a sleep disorder that has been associated with the loss of orexinergic neurons from the lateral hypothalamic area. This loss leads to dysregulated sleep and cataplexy attacks. Therapeutic options are currently limited to symptom management with pharmacotherapy and nonpharmacological approaches. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brainres.2020.146951DOI Listing

Orexin and Alzheimer's Disease: A New Perspective.

Psychiatry Investig 2020 Jun 11. Epub 2020 Jun 11.

Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

Orexin's role in human cognition has recently been emphasized and emerging evidences indicate its close relationship with Alzheimer's disease (AD). This review aimed to demonstrate recent research on the relationship between orexin and AD. Orexin's role in stress regulation and memory is discussed, with significant findings related to sexual disparities in stress response, with potential clinical implications pertaining to AD pathology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.30773/pi.2020.0136DOI Listing

Neuropsychiatric Correlates of Narcolepsy.

Curr Psychiatry Rep 2020 Jun 5;22(8):36. Epub 2020 Jun 5.

Strategic Technologies Program of the National Plan for Sciences and Technology and Innovation in the Kingdom of Saudi Arabia, Riyadh, Saudi Arabia.

Purpose Of Review: The complex nature of narcolepsy symptoms, along with the use of stimulants and anticataplectic medications, poses diagnostic difficulties in terms of underlying neuropsychiatric comorbidities. This study reviews recent evidence for the association between narcolepsy and neuropsychiatric disorders. We also critically analyze studies that have addressed the neuropsychiatric correlates of patients with narcolepsy, with a discussion of the possible pathophysiological mechanisms linking narcolepsy and neuropsychiatric disorders. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11920-020-01159-yDOI Listing
June 2020
3.238 Impact Factor

Effect of treatment on cognitive and attention problems in children with narcolepsy type 1.

Sleep 2020 Jun 6. Epub 2020 Jun 6.

Center for Sleep Medicine, Kempenhaeghe, Heeze, The Netherlands1.

Study Objective: To ascertain the presence of cognitive and attention problems in treatment naïve children with narcolepsy type 1 (NT1) and to explore whether children recently diagnosed with NT1 improve with respect to cognition and attention problems one year after regular treatment for NT1.

Methods: Fifteen treatment naïve children (7-15 years) with recently diagnosed NT1 were recruited from three sleep medicine centers in the Netherlands. The control group consisted of 15 healthy children, being frequency matched on age and gender. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/sleep/zsaa114DOI Listing

The Dual-Active Histamine H Receptor Antagonist and Acetylcholine Esterase Inhibitor E100 Alleviates Autistic-Like Behaviors and Oxidative Stress in Valproic Acid Induced Autism in Mice.

Int J Mol Sci 2020 Jun 3;21(11). Epub 2020 Jun 3.

Department of Pharmacology & Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain P.O. Box 17666, UAE.

The histamine H3 receptor (H3R) functions as auto- and hetero-receptors, regulating the release of brain histamine (HA) and acetylcholine (ACh), respectively. The enzyme acetylcholine esterase (AChE) is involved in the metabolism of brain ACh. Both brain HA and ACh are implicated in several cognitive disorders like Alzheimer's disease, schizophrenia, anxiety, and narcolepsy, all of which are comorbid with autistic spectrum disorder (ASD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms21113996DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312782PMC

Utility of measuring CSF hypocretin-1 level in patients with suspected narcolepsy.

Sleep Med 2020 Jul 21;71:48-51. Epub 2020 Mar 21.

Department of Sleep Medicine, Royal Infirmary Edinburgh, 51 Little France Crescent, Little France, EH16 4SA, UK. Electronic address:

Objectives: The patho-aetiology of narcolepsy Type I (NT1) is the loss of hypocretin-1 secreting neurons in the hypothalamus. Diagnostic criteria for NT1 include excessive daytime sleepiness (EDS) for at least three months not explained by any other condition, cataplexy and cerebrospinal fluid (CSF) hypocretin-1 concentrations lower than 110 pg/ml. In this study we evaluated the utility of measuring CSF hypocretin-1 levels in patients with suspected narcolepsy (N). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.sleep.2020.03.009DOI Listing

A Sympathetic Treatment for Obesity.

Cell Metab 2020 Jun;31(6):1043-1045

Program in Cell Signaling and Neurobiology of Metabolism, Yale University School of Medicine, New Haven, CT 06520, USA; Departments of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, CT 06520, USA; Department of Comparative Medicine, Yale University School of Medicine, New Haven, CT 06520, USA; Department of Neuroscience, Yale University School of Medicine, New Haven, CT 06520, USA. Electronic address:

Amphetamine (AMPH), mainly used in the treatment of attention deficit hyperactivity disorder and narcolepsy, has weight loss properties, although with detrimental cardiovascular effects. In this issue, Mahú et al. (2020) describe the effect of a new derivative of AMPH, "PEGyAMPH," a brain-spared anti-obesity drug that alters sympathetic activity without cardiovascular side effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cmet.2020.05.009DOI Listing

The 2009 H1N1 pandemic, vaccine-associated narcolepsy, and the politics of risk and harm.

Authors:
Venla Oikkonen

Health (London) 2020 Jun 2:1363459320925880. Epub 2020 Jun 2.

Tampere University, Finland.

The article traces the emergence of a new type of vaccine injury-vaccine-associated narcolepsy-following immunization with Pandemrix vaccine during the 2009 H1N1 pandemic in Europe. The article highlights the processual nature of vaccine injury: it shows how vaccine-associated narcolepsy emerges gradually as a recognized object through epidemiological and immunological studies as well as patient organizations' public discourses. The article argues that despite public recognition of injury, vaccine-associated narcolepsy remains an incongruous object characterized by underlying tensions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1363459320925880DOI Listing

Effect of ambient temperature on sleep breathing phenotype in mice: the role of orexins.

J Exp Biol 2020 Jun 30;223(Pt 13). Epub 2020 Jun 30.

PRISM Lab, Department of Biomedical and Neuromotor Sciences, and Center for Applied Biomedical Research, Department of Medical and Surgical Sciences, Sant'Orsola University Hospital, Alma Mater Studiorum - University of Bologna, Bologna 40126, Italy

The loss of orexinergic neurons, which release orexins, results in narcolepsy. Orexins participate in the regulation of many physiological functions, and their role as wake-promoting molecules has been widely described. Less is known about the involvement of orexins in body temperature and respiratory regulation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1242/jeb.219485DOI Listing

The role of eugeroics in the treatment of affective disorders.

Psychiatr Pol 2020 Feb 29;54(1):21-33. Epub 2020 Feb 29.

Klinika Psychiatrii Dorosłych Gdańskiego Uniwersytetu Medycznego.

Eugeroics are a relatively new class of wakefulness-promoting agents. Thegroup includes adrafinil, modafinil and armodafinil. Modafinil is the most widely used and the best studied agent. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12740/PP/OnlineFirst/90687DOI Listing
February 2020

Neurophysiological and Neurochemical Effects of the Putative Cognitive Enhancer ()-CE-123 on Mesocorticolimbic Dopamine System.

Biomolecules 2020 May 18;10(5). Epub 2020 May 18.

Department of Biomedical Sciences, Division of Neuroscience and Clinical Pharmacology, University of Cagliari, 09042 Monserrato, Italy.

Treatments for cognitive impairments associated with neuropsychiatric disorders, such as attention deficit hyperactivity disorder or narcolepsy, aim at modulating extracellular dopamine levels in the brain. CE-123 (5-((benzhydrylsulfinyl)methyl) thiazole) is a novel modafinil analog with improved specificity and efficacy for dopamine transporter inhibition that improves cognitive and motivational processes in experimental animals. We studied the neuropharmacological and behavioral effects of the -enantiomer of CE-123 (()-CE-123) and -modafinil in cognitive- and reward-related brain areas of adult male rats. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/biom10050779DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7277835PMC

Narcolepsy Type 1: What have we learned from genetics?

Authors:
Hanna M Ollila

Sleep 2020 May 22. Epub 2020 May 22.

Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.

Type-1 narcolepsy is a severe neurological disorder with distinct characteristic of loss of hypocretin neurotransmitter. Genetic analysis in type-1 narcolepsy have revealed a unique signal pointing towards autoimmune, rather than psychiatric origin. While type-1 narcolepsy has been intensively studied the other sub types of hypersomnolence, narcolepsy and hypersomnia are less thoroughly understood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/sleep/zsaa099DOI Listing

CSF and serum ferritin levels in narcolepsy type 1 comorbid with restless legs syndrome.

Ann Clin Transl Neurol 2020 06 20;7(6):924-931. Epub 2020 May 20.

Sleep-Wake Disorders Unit, Department of Neurology, Gui-de-Chauliac Hospital, CHU Montpellier, Montpellier, France.

Objectives: To investigate whether cerebrospinal fluid (CSF) and serum ferritin levels differ between patients with narcolepsy type 1 (NT1) comorbid with restless legs syndrome (RLS) or periodic leg movements during sleep (PLMS), and patients with NT1 or controls without comorbid RLS or PLMS.

Methods: Sixty-six drug-free patients with NT1 (44 males, age 38.5 years [14-81]) were enrolled, including 20 with RLS, 18 with PLMS index ≥15/h (six with both RLS and PLMS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acn3.51056DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317640PMC

Metabolome analysis using cerebrospinal fluid from narcolepsy type 1 patients.

Sleep 2020 May 15. Epub 2020 May 15.

Department of Psychiatry and Behavioral Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.

Narcolepsy type 1 (NT1) is a hypersomnia characterized by excessive daytime sleepiness and cataplexy. Inappropriate regulation of fatty acid metabolism has been suggested to be involved in the pathophysiology of NT1, but the detailed mechanisms remain uncertain. Here we performed a metabolomic analysis of cerebrospinal fluid samples from 14 NT1 and 17 control subjects using a novel capillary electrophoresis coupled with Fourier transform mass spectrometry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/sleep/zsaa095DOI Listing

SMPD1 variants do not have a major role in rapid eye movement sleep behavior disorder.

Neurobiol Aging 2020 Sep 18;93:142.e5-142.e7. Epub 2020 Apr 18.

Department of Human Genetics, McGill University, Montréal, Quebec, Canada; Montreal Neurological Institute, McGill University, Montréal, Quebec, Canada; Department of Neurology and Neurosurgery, McGill University, Montréal, Quebec, Canada. Electronic address:

Mutations in the sphingomyelin phosphodiesterase 1 (SMPD1) gene were reported to be associated with Parkinson's disease and dementia with Lewy bodies. In the current study, we aimed to evaluate the role of SMPD1 variants in isolated rapid eye movement sleep behavior disorder (iRBD). SMPD1 and its untranslated regions were sequenced using targeted next-generation sequencing in 959 iRBD patients and 1287 controls from European descent. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neurobiolaging.2020.04.005DOI Listing
September 2020
5.013 Impact Factor

Reply to Maski K et al. commentary on diagnosis of central disorders of hypersomnolence: Challenges in defining central disorders of hypersomnolence.

Sleep Med Rev 2020 Apr 26;52:101326. Epub 2020 Apr 26.

Sleep-Wake Disorders Center, National Reference Network for Narcolepsy, Department of Neurology, Gui-de-Chauliac Hospital, INSERM, U1061, CHU Montpellier, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.smrv.2020.101326DOI Listing

Reply to Micoulaud-Franchi et al. Commentary on diagnosis of central disorders of hypersomnolence: From clinic to clinic via ontology and semantic analysis on a bullet point path.

Sleep Med Rev 2020 Apr 26;52:101329. Epub 2020 Apr 26.

Sleep-Wake Disorders Center, National Reference Network for Narcolepsy, Department of Neurology, Gui-de-Chauliac Hospital, INSERM, U1061, CHU Montpellier, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.smrv.2020.101329DOI Listing

Observation and interview-based diurnal sleepiness inventory for measurement of sleepiness in patients referred for narcolepsy or idiopathic hypersomnia.

J Clin Sleep Med 2020 May 14. Epub 2020 May 14.

Center for sleep Medicine and Respiratory Diseases, Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, France.

Study Objectives: First, to determine whether the three-item ODSI (Observation and interview based Diurnal Sleepiness Inventory) measures the degree of excessive daytime sleepiness (EDS) in patients with suspected narcolepsy or idiopathic hypersomnia (IH). Second, to assess the correlation between the ODSI and the Epworth Sleepiness Scale (ESS) as well as objective polysomnographic measurements. Third, to test the accuracy of the ODSI to detect narcolepsy or idiopathic hypersomnia (narcolepsy/IH) compared to the ESS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5664/jcsm.8574DOI Listing

Narcolepsy with resolution of cataplexy and persisting orexin deficiency.

J Clin Sleep Med 2020 May 14. Epub 2020 May 14.

Sleep and Brain Plasticity Centre, Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London, United Kingdom.

None: Narcolepsy type one (NT1) is a debilitating chronic neurological disorder, whose main symptoms of excessive daytime sleepiness (EDS) and cataplexy may partially improve with time, but typically do not fully resolve. The irreversible loss of orexin neurons is considered to be the pivotal mechanistic link underlying the development of cataplectic attacks in NT1. We here describe a case of untreated NT1 with low cerebrospinal orexin levels ( <50 pg/mL), where cataplexy fully resolved in the first 5-6 years after disease onset, while EDS persisted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5664/jcsm.8572DOI Listing

Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses.

Clin Drug Investig 2020 Jul;40(7):603-615

Discovery Research, Suven Life Sciences Ltd., Serene Chambers, Road # 7, Banjara Hills, Hyderabad, 500 034, India.

Background And Objective: SUVN-G3031 is a novel, potent, and selective histamine-3 receptor (HR) inverse agonist in development for the treatment of narcolepsy. Our objective was to characterize the safety, tolerability, and pharmacokinetics of SUVN-G3031 in healthy young adults after single and multiple doses, and to evaluate the effect of food, gender, and age on the pharmacokinetics.

Methods: A single ascending dose (SAD) and a multiple ascending dose (MAD) study for 14 days was conducted in healthy young adults using a randomized, double-blind study design. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40261-020-00920-8DOI Listing

Protocols of a diagnostic study and a randomized controlled non-inferiority trial comparing televisits vs standard in-person outpatient visits for narcolepsy diagnosis and care: TElemedicine for NARcolepsy (TENAR).

BMC Neurol 2020 May 11;20(1):176. Epub 2020 May 11.

IRCCS Istituto delle Scienze Neurologiche di Bologna, Via Altura 3, Bologna, Italy.

Background: Narcolepsy is a rare chronic sleep disorder that typically begins in youth. Excessive daytime sleepiness is the main disabling symptom, but the disease is often associated with severe endocrine-metabolic and psychosocial issues, worsened by a long diagnostic delay, requiring a multidisciplinary approach. The scarcity of reference Sleep Centres forces the patient and family to travel for seeking medical consultations, increasing the economic and psychosocial burden of the disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12883-020-01762-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212602PMC

Nonpharmacologic Management of Excessive Daytime Sleepiness.

Authors:
Matthew R Ebben

Sleep Med Clin 2020 Jun;15(2):195-203

Department of Neurology, Center for Sleep Medicine, Weill Cornell Medical College of Cornell University, 425 East 61st Street, 5th Floor, New York, NY 10065, USA. Electronic address:

Unlike other reviews written on this topic, the focus of this article is primarily on nonpharmacologic treatments for daytime sleepiness that is not secondary to other medical or psychological conditions. To provide an appropriate background on primary excessive daytime sleepiness, what is considered optimal sleep in terms of sleep duration, sleep insufficiency, and sleep need is discussed in detail. This discussion is followed by an examination of the behavioral strategy of banking sleep. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jsmc.2020.02.018DOI Listing

Pharmacologic Management of Excessive Daytime Sleepiness.

Sleep Med Clin 2020 Jun;15(2):177-194

Sleep and Circadian Neurobiology Laboratory, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford University, Palo Alto, CA, USA. Electronic address:

Excessive daytime sleepiness (EDS) is related to medical and social problems, including mental disorders, physical diseases, poor quality of life, and so forth. According to the International Classification of Sleep Disorders, Third Edition, diseases that result from EDS are narcolepsy type 1, narcolepsy type 2, idiopathic hypersomnia, hypersomnia due to a medical disorder, and others. EDS is usually treated using amphetamine-like central nervous system stimulants or modafinil and its R-enantiomer, armodafinil, wake-promoting compounds unrelated to amphetamines; a variety of new drugs are under development. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jsmc.2020.02.006DOI Listing

Role of Brown Adipose Tissue in Adiposity Associated With Narcolepsy Type 1.

Front Endocrinol (Lausanne) 2020 16;11:145. Epub 2020 Apr 16.

Division of Endocrinology, Department of Medicine, Leiden University Medical Center, Leiden, Netherlands.

Narcolepsy type 1 is a neurological sleep-wake disorder caused by the destruction of orexin (hypocretin)-producing neurons. These neurons are particularly located in the lateral hypothalamus and have widespread projections throughout the brain, where they are involved, e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fendo.2020.00145DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176868PMC

Variants in the Niemann-Pick type C gene NPC1 are not associated with Parkinson's disease.

Neurobiol Aging 2020 Sep 8;93:143.e1-143.e4. Epub 2020 Apr 8.

Montreal Neurological Institute, McGill University, Montréal, Quebec, Canada; Department of Neurology and neurosurgery, McGill University, Montréal, Quebec, Canada; Department of Human Genetics, McGill University, Montréal, Quebec, Canada. Electronic address:

Biallelic variants in NPC1, a gene coding for a lysosomal transmembrane protein involved in cholesterol trafficking, may cause Niemann-Pick disease type C (NPC). A few cases of NPC1 variant carriers with Parkinson's disease (PD) have been reported. In addition, pathologic studies have demonstrated phosphorylated alpha-synuclein and Lewy pathology in brains of NPC patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neurobiolaging.2020.03.021DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302975PMC
September 2020
5.013 Impact Factor

Constructing gene network for type 1 narcolepsy based on genome-wide association study and differential gene expression analysis (STROBE).

Medicine (Baltimore) 2020 May;99(18):e19985

Department of Clinical Neurology, Peking University, People's Hospital.

Although many genes that affect narcolepsy risk have been identified, the interactions among these genes are still unclear. Moreover, there is a lack of research on the construction of the genetic network of narcolepsy. To screen candidate genes related to the onset of narcolepsy type 1, the function and distribution of important genes related to narcolepsy type 1 were studied and a gene network was constructed to study the pathogenesis of narcolepsy type 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000019985DOI Listing

Sleep Disorders in Adolescents.

Authors:
Sujay Kansagra

Pediatrics 2020 May;145(Suppl 2):S204-S209

Duke University Medical Center, Durham, North Carolina

Chronic sleep deprivation is a common, treatable condition among adolescents. Growing literature supports a myriad consequences that impact overall health, behavior, mood, and academic performance in this vulnerable age group during a time when there are rapid changes in physical development and emotional regulation. This article reviews the epidemiology and health effects of sleep deprivation in adolescents as well as common disorders leading to sleep loss and evidence to support treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1542/peds.2019-2056IDOI Listing

Incidence and duration of common, early-onset adverse events occurring during 2 randomized, placebo-controlled, phase 3 studies of sodium oxybate in participants with narcolepsy.

J Clin Sleep Med 2020 May 1. Epub 2020 May 1.

Jazz Pharmaceuticals, Palo Alto, California.

Study Objectives: To determine the time course and duration of common, early-onset treatment-emergent adverse events (TEAEs) associated with sodium oxybate (SXB) use in adults with narcolepsy.

Methods: These were post hoc analyses of two 8-week, randomized, double-blind, placebo-controlled trials. In SXB-15, participants (N=246) received daily placebo (n=60) or SXB (n=186), initiated at 4. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5664/jcsm.8530DOI Listing

LC-MS/MS method for the quantification of SUVN-G3031, a novel H3 receptor inverse agonist for narcolepsy treatment.

Bioanalysis 2020 Apr 30;12(8):533-544. Epub 2020 Apr 30.

Biopharmaceutical Research, Suven Life Sciences Ltd, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India.

A LC-MS/MS method was validated for the quantification of SUVN-G3031, a novel H3 receptor inverse agonist in clinical development for the treatment of patients with narcolepsy, with and without cataplexy. SUVN-G3031 was extracted from plasma following acetonitrile protein precipitation, separated by Ultra HPLC and quantified using positive ESI-MS/MS. The method was linear across the range of 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4155/bio-2020-0020DOI Listing

Narcolepsy and COVID-19: sleeping on an opportunity?

J Clin Sleep Med 2020 Apr 29. Epub 2020 Apr 29.

Sleep and Health Research Program, Department of Psychiatry, University of Arizona, Tucson, Arizona.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5664/jcsm.8520DOI Listing